Overview
Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to attack cancer, autoimmune, and inflammatory diseases. It holds a portfolio of candidates in stages of development ranging from pre-clinical to late-stage trials. Its first marketed product is Ofatumumab, for the treatment of a type of chronic lymphocytic leukemia. Genmab is also working on Daratumumab, a monoclonal antibody that holds the potential
...
Read More to kill multiple myeloma cells. The company has licensing and development partnerships with several international pharmaceutical and biotech companies. Genmab was founded in 1999.
Read Less
Read More to kill multiple myeloma cells. The company has licensing and development partnerships with several international pharmaceutical and biotech companies. Genmab was founded in 1999.
Read Less
Jan van de Winkel
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Commercial physical research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
Actual
$3.05 billion
Actual
30.67%
80.24%
$45,811
DEC
?
?
OMXCop:GMAB
Contacts
Get in Touch with 11 Principals*
-
Jan van de WinkelManaging Director
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$3.05 billion
USD
Actual
1 USD = 7.0532 DKK
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $1,102 | $1,046 | $555 |
| Net Investing Cash | -$1,405 | -$182 | -$391 |
| Net Financing Cash | -$556 | -$86 | -$112 |
| Net Change in Cash | -$858 | $779 | $51 |
| Cash at Beginning of Period | $2,108 | $1,403 | $1,270 |
| Cash at End of Period | $1,398 | $2,108 | $1,403 |
| Capital Expenditure | -$43 | -$53 | -$45 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $1,398 | $2,108 | $1,403 |
| Accounts Receivable | $934 | $701 | $810 |
| Inventories | $9 | $8 | $ |
| Other Current Assets | $1,608 | $1,881 | $1,788 |
| Asset Summary | |||
| Total Current Assets | $3,949 | $4,698 | $4,001 |
| Tangible Fixed Assets | $268 | $233 | $187 |
| Intangible Assets | $1,750 | $14 | $ |
| Total Assets | $45,811 | $35,289 | $30,119 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $ | $ | $ |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $753 | $352 | $258 |
| Liability Summary | |||
| Total Current Liabilities | $753 | $352 | $258 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $1,292 | $522 | $402 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $9 | $9 | $9 |
| Retained Earnings | $3,339 | $2,697 | $2,100 |
| Equity Summary | |||
| Total Equity | $5,203 | $4,482 | $3,868 |
| Shares Outstanding | 63,540,179 | 65,330,365 | 65,371,625 |